Objective: HIV infection is currently regarded as a global chronic disease. The purpose of this study was to assess the direct cost of illness per patient per year in Greece. Methods: A retrospective study for the estimation of the direct cost of HIV infection was performed from the third-party payer perspective. Data from 447 patients monitored in a general hospital of Athens were collected from their medical records. The survey involved all services and treatments that patients (stratified into three health states according to the number of CD4 cells/ml as defined by the Centers for Disease Control and Prevention classification system for HIV infection) received in 1 year, as well as demographic data. Results: The annual direct cost per patient was calculated at €6859 Ϯ €4699. Antiretroviral therapy cost was estimated at €5741, while the annual cost of providing health care services regardless of health state was computed at €1118, with laboratory investigation and imaging studies representing €924 (13.5%), outpatient visits €34 (0.5%), and hospitalization €160 (2.3%) of total cost, respectively. Overall, direct cost per patient was found to increase as the CD4 T lymphocytes decreased, leading to prolonged hospitalization and an increase in the number of laboratory tests. Direct cost for patients with more than 500 CD4 cells/μl was estimated at €6067, whereas for those with 200 to 499 cells/μl and less than 200 cells/μl, it was assessed at €6857 and €7654, respectively. Conclusions: The direct cost of HIV infection per patient increased as CD4 T lymphocytes decreased. The largest part of expenses was attributed to antiretroviral therapy, followed by laboratory tests/imaging studies, hospitalization, and finally outpatient visits.
Introduction
The first cases of HIV infection were reported in the early 1980s in the United States . As was later discovered, however, the virus appeared several decades earlier and was transmitted to humans by Pan troglodytes troglodytes, a chimpanzee species [1, 2] . The HIV infection has captured since then the interest of researchers who bestir themselves in the field of medicine, social sciences, and health economics because its complex pathology affects all these sectors.
Since the 1980s, the transmission of the virus resulted in rapid and fatal spread within a relatively short time. As soon as the virus is transmitted through sexual fluids, blood, or breast milk, it enters host cells with specific mechanisms and starts the replication of the genetic material, resulting in continuous proliferation. Antiretroviral drugs interfere in different stages of the virus life cycle by preventing multiplication. The nonadministration of antiretroviral agents engenders faster disease progression, and finally patient's end of life because of a drop in the immune system [3, 4] .
Effective disease management represents a challenge for practitioners, as hitherto, current therapies were unable to eradicate the virus. Moreover, the gradual weakening of infected patients' immune system sets important barriers regarding effective disease monitoring [5] . With the advent of antiretroviral therapy in the mid-1990s, patients' life expectancy and quality of life increased, thus leading to an ever-increasing cost of HIV infection, attributed to the high cost of antiretroviral therapy and to the specialized inpatient and outpatient health services required for the monitoring of HIV-positive patients [6, 7] .
As a result, health care managers, policymakers, and practitioners need to have up-to-date data on costs, especially when considering a country such as Greece where austerity measures have been undertaken, reducing the available resources. Therefore, funds' allocation needs to be more effective, responding to patients' needs, especially when it involves a disease with so many particularities [8] . The growing number of HIV seropositives, antiretroviral therapy, and the chronic nature of HIV infection itself generate the constant rise in expenditures and lead current research to focus on the cost estimation of different parameters that contribute to the cost of the disease [9] .
The present study aimed at estimating all health care resources consumed by HIV-infected patients in Greece, on an annual basis, as well as their respective costs. The main objective of this analysis was to provide an up-to-date estimation of HIV-infection's direct cost in Greece to redraw and improve the health services provided to this particularly vulnerable patient population.
Methods

Research Design
A retrospective study was performed to estimate the direct cost of HIV infection. In Greece, HIV patients are exclusively monitored by HIV specialists in infectious diseases units of public hospitals. Therefore, all costs associated with HIV management involve health resources consumed in a public hospital setting. Direct medical costs and antiretroviral therapy costs were assessed from a third-party payer perspective.
Study Participants/Patients
The sample was composed of subjects monitored in the Infectious Diseases Unit of a general hospital in Athens. Patients aged 18 years or older, followed in the HIV special unit from July 2, 2012, to July 2, 2013, were included in the study. Out of 489 patients monitored in the unit, 447 finally met the inclusion criteria because clinical data within the aforementioned period were not available for 42 patients. All ethical requirements were met, and each participant returned his or her written informed consent. Data were obtained from their medical records, and medical confidentiality was preserved throughout the course of the survey.
Patients were stratified according to the CD4 T-lymphocyte count at the beginning of the study period. Three main cell-count categories emerged in accordance with the Centers for Disease Control and Prevention classification system for HIV infection. The first category included patients with 500 or more CD4 cells/μl, the second one patients with 200 to 499 cells/μl, and finally the third one patients with less than 200 cells/μl.
Data Collection
The following data were collected through medical records: demographic and clinical characteristics (age, nationality, date of initial diagnosis, sex, mode of transmission, HIV RNA levels, and CD4 T-lymphocyte count), outpatient visits, hospitalizations, laboratory tests and imaging studies, as well as antiretroviral drugs. Outpatient visits only included visits to specialist physicians because in Greece, HIV-infected patients are exclusively monitored by specialists and not by general practitioners. Hospitalizations comprised all admissions related to HIV infection, those recorded in the intensive care unit included. Laboratory investigation subsumed routine laboratory tests that were performed twice a year (CD4 T-lymphocyte count, HIV RNA test, full blood cell count, routine blood biochemistry) and any other test patients were submitted to depending on their health status. Finally, regarding pharmaceutical treatment, only antiretroviral therapy was taken into account.
Cost Estimation
The analysis was performed from a third-party payer perspective and involved all costs related to HIV patients' follow-up. Expenditures were divided into two main categories: medication costs and costs associated with health care services that HIV-infected patients received in the hospital setting. To calculate these costs, the frequency of each treatment or health service used was multiplied by the associated charge. All costs were evaluated in euros and in accordance with the latest Greek price bulletin of August 2013 [10] .
Drug costs included the cost of antiretroviral drugs used to treat HIV infection and did not incorporate prophylactic or other medications that HIV-infected patients may have been prescribed. All prescribed treatments were available from the medical records. Cost calculations were based on reimbursable prices. These prices were then multiplied by the amount of drugs that patients received during the reporting year [11] .
Costs associated with health care services provided through the Specialized Unit included costs for outpatient visits, hospitalization, laboratory investigation, and imaging tests. Outpatient visits concerned regular HIV clinic visits. Hospitalization costs were obtained via the official Greek price list, based on admission diagnosis, according to the International Statistical Classification of Diseases, 10th Revision, and reported on patient's medical record [12] . The cost of laboratory investigation, including all laboratory tests and any other test that HIV-infected patients may have been submitted to, was calculated as cost per test per patient [10] .
Results
Patient Characteristics
In a total of 447 patients, 383 (86%) were men and 64 (14%) were women, of which the great majority was of Greek nationality (403 patients), whereas other patients were from Africa, Eastern Europe, Western Europe, Middle East, and Central and South America, in descending order. The mean age of participants was 45 Ϯ 11.86 years. Taking into account the age classification, most patients were from the 36-to 50-year-old age group (N ¼ 203, 45%), followed by the 51-to 65-year-old age group (N ¼ 115, 26%). Nearly 106 patients (24%) belonged to the 18-to 35-year-old age group and finally only 23 (5%) were aged 66 years or older. For the mode of HIV transmission, five main categories were distinguished: homosexual transmission (being the most representative, as for 273 [61%] patients, the virus was transmitted through this mode), heterosexual contact (N ¼ 117, 26%), intravenous drug users (N ¼ 14, 3%), homosexual intravenous drug users (N ¼ 5, 1%), and unknown transmission route (N ¼ 38, 9%) ( Table 1) .
As mentioned above, patients were stratified into three categories according to the Centers for Disease Control and Prevention classification system for HIV infection, based on the CD4 T-lymphocyte count. The CD4 count considered to classify the participants was the most recent to the starting date of the survey. The great majority of the cohort (N ¼ 288, 64%) was classified in the first category, including patients with 500 or more cells/μl. Patients having between 200-499 cells/μL represented 29% of the sample (128 patients), while 31 participants, counting less than 200 cells/μL were included in the third category, representing 7% of the sample. The mean CD4 T-lymphocyte count, overall health states, was 638 cells/μl (Table 1) .
Health Care Utilization
Health care utilization showed that, some exceptions aside, patients with lower CD4 levels presented higher use of health services both in routine laboratory tests, such as viral load tests or CD4 count tests, and in all other tests that patients may have been submitted to. The same pattern was held for outpatient visits. Patients who counted lower CD4 levels, being more prone to infectious diseases, presented a higher percentage of hospital admissions. Patients with lower CD4 levels also suggest a higher percentage of hospital admissions because they are more prone
to infectious diseases. Therefore, for patients with less than 200 cells/μl, 71 hospital admissions/100 patients were observed, in contrast to participants stratified in the first category (Z500 cells/ μl) and the second category (200-400 cells/μl), presenting 10 and 12 hospital admissions/100 patients, respectively. Hence, 61% and 59% more hospital admissions were attributed to patients with less than 200 cells/μl compared with those with more than 500 cells/μl and those presenting between 200 and 499 cells/μl, respectively. Health care utilization by CD4 cell-count stratum is presented in Table 2 .
Cost Calculations
Total costs
Total direct costs including outpatient visits, hospitalization, laboratory/imaging tests, and drug costs were estimated at €6860 Ϯ €4699 per patient on an annual basis regardless of the CD4 levels. A trend toward higher total cost was noticed when moving from the first category (Z500 CD4 cells/ml) to the third category (o200 cells/ml), even though not statistically significant. The cost of antiretroviral therapy was estimated at €5741.11 and represented 83.7% of the total direct costs. Costs of both health care services provided and antiretroviral treatment increased as the CD4 levels decreased. More specifically, the CD4 count appeared to particularly correlate with laboratory/imaging tests' and hospitalization's costs (P o 0.05). All costs were estimated in 2013 euros, as presented in Table 3 .
Antiretroviral therapy
Out of 447 patients, 81 were treatment-naive, having never received any antiretroviral therapy during the considered year or before. Among 366 experienced patients, 26 switched therapy within the aforesaid time horizon. Total annual expenditure of antiretroviral therapy per patient, regardless of the CD4 count, was calculated at €5741, representing 83.7% of the total direct costs.
Cost of health care services provided in the hospital setting
The cost of health care services provided in the hospital included the cost of intensive care unit and non-intensive care unit hospitalizations, laboratory/imaging tests, as well as outpatient visits to HIV specialist physicians and was estimated at €1118 Ϯ €470 regardless of the CD4 count. Laboratory/imaging tests represented the largest part of this cost category and were assessed at €924, followed by hospitalization (€160.31) and outpatient visits (€34).
Discussion
In a time when many countries are confronted with social and economic turbulence, resources are becoming even scarcer; thus, the need for effective organization and management of health services, based on the population's needs, is compelling. To achieve these objectives, the main tools used are costing methods, which enable policymakers to take decisions according to patients' requirements. The estimation of the economic burden of diseases is therefore the first step in planning specialized health services. The present study seems to be the first over the last 15 years that attempts to estimate the health resources consumed by HIV-infected patients in Greece and their associated costs. Therefore, it cannot be compared with previous studies performed in the same health care setting. Several surveys, however, have been undertaken in Europe and the United States.
Such studies appear to have great importance, especially when considering chronic diseases that exhibit several diversities 
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and complexities, such as HIV infection. The present study assessed the annual direct cost of HIV infection per patient in Greece and, furthermore, compared the costs attributed to different health states. Findings suggested that both total direct cost and partial costs associated with several resources consumed increased as the count of CD4 T lymphocytes decrease. Most patients of the sample, however, seemed to have more than 500 cells/μl, indicating adequate follow-up. Regardless of the health state considered, the total direct cost was calculated at €6860 per patient per year, while the largest part was attributed to antiretroviral therapy, estimated at €5741 and representing 83.7% of the total cost. The reported results of this survey seemed to be in line with other published studies conducted in Europe, Canada, and the United States. Nevertheless, any differences observed among these studies were due to unlike methodological approaches, and to diversions regarding the variables considered, in order to assess the cost of illness.
Krentz and Gill [13] studied the direct costs of newly diagnosed patients with less than 350 CD4 cells per mm 3 in Southern Alberta in Canada from 1995 to 2010. The cost of treatment for these individuals was $17.028 per year, while for early diagnosed patients the cost was $10,968 per year (expressed in Canadian dollars adjusted to 2009). The direct cost estimation included the cost of hospitalization, outpatient visits, laboratory tests, and drug treatment (including non-and antiretroviral therapy). Despite the fact that by providing antiretroviral treatment, the CD4 T-lymphocyte levels gradually increased over time, the cost still remained high, with hospitalization costs representing 64% of total expenditures [13] . The same authors [14] conducted, from 2000 to 2008, a study in which they compared the health care costs between local and immigrant HIV patients of Southern Alberta. Drug, inpatient, and outpatient costs were included, and final results were expressed in mean costs per patient per month in 2009 Canadian dollars. Findings showed no statistically significant difference between Canadian and foreign patients, with direct cost calculated at $1174 and $1067, respectively. Hutchinson et al. [15] assessed the cost of HIV infection in the United States focusing on racial and ethnic differences. This study, beyond direct costs (hospitalization, non-and antiretroviral therapy, laboratory tests, outpatient visits), estimated the productivity loss due to mortality. Patients diagnosed early and under antiretroviral treatment presented higher life expectancy (24.4 years), and lifetime cost was computed at $361,944. However, patients who were not prescribed any antiretroviral agents had an average life expectancy of 12.4 years and estimated lifetime direct costs of $145,218 [15] .
Several European studies of HIV infection cost estimation have been conducted over the last few years. In Sweden, Ghatnekar et al. [16] estimated the cost of antiretroviral drugs, laboratory tests, outpatient visits, and hospitalization. The study included data from 285 patients, monitored in the Sahlgrenska University Hospital, from 2000 to 2005. The average cost per patient and per month was €1069, 51% of which was attributed to antiretroviral therapy, 22% to hospitalization, 19% to outpatient visits, and 7% to laboratory tests. In addition, it was observed that all partial costs, besides the cost of antiretroviral therapy, increased with the decrease in the number of CD4 T lymphocytes [16] . Colin et al. [17] assessed the cost of managing HIV infection in France, using data from French hospital database and including 50% of HIV patients from 2003 to 2005. The study evaluated the cost of antiviral agents, antiparasitic drugs, antimycobacterial agents, and hospitalizations. The mean health care costs per patient-year seemed to decrease as CD4 cell-count increased and varied from €34,286 to €12,361 [17] . In Germany, Mostardt et al. [18] performed an 18-month prospective study estimating the cost of HIV infection from 2006 to 2009. About 518 patients from 17 ambulatory care centers were included. The study assessed the annual health care cost from the societal and statutory perspectives. The average annual health care costs were €23,298 per patient when the analysis was performed from the first perspective and €19,103 when the analysis was performed from the second perspective. As anticipated, most of the estimated cost was associated with antiretroviral therapy [18] .
The aforementioned surveys present some patterns that are alike for most of them but also several differences. The results of the studies conducted denoted that the deficiency of the immune system and therefore the decrease in CD4 cell count resulted in higher costs. In addition, the largest part of total direct cost of HIV infection was in all cases attributed to antiretroviral therapy. Indeed, the cost of providing medical care to HIV patients has definitely increased since the introduction of highly active antiretroviral therapy [19, 20] . Nevertheless, cost estimations also presented great differences and heterogeneities. They differed in the nature of the study itself, the sample considered, and especially the characteristics of patients, the country's health system, the components of the estimated cost, as well as unit costs [21] . As a matter of fact, the aforestated studies used a different approach for the estimation of HIV infection's direct cost. As a result, comparing the findings of the different studies seems quite challenging; however, some general conclusions can certainly be drawn [22, 23] . The present survey seems to be in line with the European studies regarding the overall results; nonetheless, some differences can be distinguished. Our findings suggested that 83.7% of the direct cost was due to antiretroviral therapy and that only 2.3% was attributed to hospitalization expenditures. In the studies conducted in Sweden, France, and Germany, the results seemed to be comparable because in all cases, hospitalization rates seemed to increase as the CD4 levels decreased, and the highest cost rates were also attributed to drugs. Especially in the case of Germany, it was found that 89% of the direct cost was due to antiretroviral therapy, which is very close to our results. However, hospitalization costs were about three times higher than our estimations, representing 7% of total direct cost. Therefore, such divergences could be considered consequences of the previously mentioned methodological differences. NS, not significant.
Possible limitations of the present study could include the retrospective documentation of health care resources used by patients, which could potentially imply lack of evidence. In addition, the survey did not include indirect and hidden costs of the disease, as well as some variables such as coinfections, which definitely have an impact in both clinical and economic terms. The analysis was performed from a third-party payer perspective, and therefore the study does not reflect market prices and indirect costs as mentioned above. Finally, results of the present study eventually cannot be generalized to the overall population; however, they can be regarded as representative of the cost that HIV infection generates in Greece. Moreover, it is the first study over the last 15 years undertaken in Greece; thus, it can be used as a reference for further studies, not only for Greece but also for different countries and health care systems.
In summary, the direct cost of HIV infection seems to be quite high considering its chronic character. The total cost appears to increase, in line with the immune system's deficiency, as patients become more prone to opportunistic infections. The methodology of the present study enables the extrapolation of results to other countries because the care process of HIV infection, subsequent health resources consumed, and different types of expenses are based on current guidelines for HIV management. Therefore, the outcomes of the cost analysis performed can be comparable to those of different health care systems, and could also be used as a reference for further studies. Finally, efforts should be focused on the enhancement of preventions and early diagnosis. The reinforcement of such health policies could significantly reduce costs of HIV infection by controlling the spread and life cycle of the virus.
